<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03737136</url>
  </required_header>
  <id_info>
    <org_study_id>SMBU11254/B</org_study_id>
    <nct_id>NCT03737136</nct_id>
  </id_info>
  <brief_title>Comparison Between Bortezomib and Rituximab Plus Plasmapheresis in AMR</brief_title>
  <official_title>Comparison Between Rituximab + PLX + IVIG With and Without Bortezomib in the Treatment of Antibody Mediated Kidney Transplanted Rejection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic-active antibody-mediated rejection (cAMR) due to de novo or pre-formed donor specific
      antibody (DSA) is currently considered the main cause of long-term allograft losses.Based on
      the aim of reducing or eliminating DSA, some proposed different therapeutic regimens for cAMR
      treatment. All of these protocols were derived from previous experience using acute
      antibody-mediated rejection and desensitization protocols, and mainly consisted of steroids,
      plasma exchange (PE), IVIG and RTX in various modalities. More recently, bortezomib was also
      proposed.To evaluate the role of a therapeutic regimen with plasma exchange, intravenous
      immunoglobulins and rituximab with or without Bortezomib in chronic-active antibody-mediated
      rejection (cAMR) settings this study designed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      20 kidney transplant recipients (KTRs) with a diagnosis of cAMR in a prospective randomized
      clinical trial will be recruited in two arms

      : ten KTRs treated with plasmapheresis, intravenous immunoglobulins and rituximab
      (PE-IVIG-RTX group) vs 10 patients receiving the same therapy plus Bortezomib. Differences
      between transplanted kidney survival and functional outcomes 6 mo after diagnosis and
      histological features and donor-specific antibody (DSA) characteristics (MFI ) will be
      investigated between two arms.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Anticipated">August 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>graft survival</measure>
    <time_frame>at month 6 following diagnosis</time_frame>
    <description>Glomerular Filtration Rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal functional tests</measure>
    <time_frame>at month 6 following diagnosis</time_frame>
    <description>Serum Cr</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Grading of antibody mediated rejection regarding Banff criteria in pathology</measure>
    <time_frame>at month 6 following diagnosis</time_frame>
    <description>kidney biopsy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DSAs-MFI</measure>
    <time_frame>at month 6 following diagnosis</time_frame>
    <description>Serum Test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Antibody-mediated Rejection</condition>
  <arm_group>
    <arm_group_label>Plasmapheresis</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>5 Sessions Plasmapheresis and 100 mg/kg Intra venous immunoglobulin at the end of each session and one dose 375mg/m2 rituximab at the end of last session</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Plasmapheresis plus Bortezomib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug 5 Sessions Plasmapheresis and 100 mg/kg Intra venous immunoglobulin at the end of each session and one dose 375ml/m2 rituximab at the end of last session plus bortezomib Injections 1.3mg/m2 intravenously on days 1, 4, 8, and 11</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>one cycle of bortezomib (each cycle: 1.3mg/m2 intravenously on days 1, 4, 8, and 11)</description>
    <arm_group_label>Plasmapheresis plus Bortezomib</arm_group_label>
    <other_name>Velcade</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients presented with renal biopsy demonstrating ABMR in the absence of
             T-cell-mediated rejection

        Exclusion Criteria:

          -  Mixed AMR and T cell rejection

          -  do not sign the consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shahid Beheshti MU sbmu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nooshin Dalili, Dr</last_name>
    <phone>00989122404331</phone>
    <email>nooshindalili4@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>SBMU</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohsen Nafar, Dr</last_name>
      <phone>00989122404331</phone>
      <email>nooshindalili4@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 4, 2018</study_first_submitted>
  <study_first_submitted_qc>November 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2018</study_first_posted>
  <last_update_submitted>July 27, 2020</last_update_submitted>
  <last_update_submitted_qc>July 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shahid Beheshti University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>nooshin dalili</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>transplantation</keyword>
  <keyword>plasmapheresis</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

